Clinigen Share Discussion Threads

[gucci] 06/3/2013 17:51

thanks arc

[arc en ciel] 06/3/2013 17:22

gucci

According to post 96 above, it is 0.6p per share (less than 0.3%).

Not enough to make a difference but the board is probably keeping their (hopefully product acquisition) powder dry.

[ygor705] 06/3/2013 15:26

Made 9p before exceptionals in the 1st half which probably means that it will make even more in the 2nd. With one or more acquisitions for cash probably in the pipeline 20p plus of earnings per anim looks very doable. On that basis this share still looks undervalued.

[snatander] 06/3/2013 14:19

looking for @£4 for these

[cfro] 06/3/2013 14:11

Up nicely today and this really is gaining traction now. As scsw state that one 'right' deal will catapult the company into the big league.

Just a matter of having some patience and letting the management make the right decisions. When the deal comes (which could come any day) the shares will soar imo.

[gucci] 06/3/2013 10:56

how much is the divi gbb483?

[gbb483] 06/3/2013 10:37

... and the share price continues up.

[gbb483] 05/3/2013 11:28

Ex-Div tomorrow.

[cfro] 02/3/2013 18:35

Small co Share Watch are very keen on CLIN and back in the November issue they had this to say......

"One company that we think is going to spectacularly catch the imagination of investors is Clinigen......Over the past three years the group sales have already grown four-fold....."

And

"Pretax profit has lifted nine fold from £1.22M to £10.25M in that time but speaking to chief executive Peter George one gets the impression that the best is yet to come and he is likely to use acquisitions to give a powerful fillip to the already fast growth rate....."


The main product, Foscavir which is hughly cash generative and has margins of 82%,and we know that they are on the war path for other such like products. Disapointing to date that they havent thus far signed anything up but we do know that management refuse to over pay. 2 time sales was the price payed for Foscavir and the range they consider is 1.75 - 2.75 times sales. And according to scsw.....

"George says that he has four sets of discussions at an advanced stage. However he wont just pay any old price and recently walked away from another involving a US licence relating to metastatic breast cancer..."

So, with no more deals tied up to date we can only assume they have 'walked away' but their seems plenty more deals to look at and it can only be a matter of time before something comes up i would think.

SCSW finish the excellent article by saying this which sums up the situation perfectly imo.......

"We have yet to see forecasts for this year as the company is fresh to the market but they hardly matter because there is a soon to be unveiled purchase of a new drug which could have the same implications as a big strike for a small oil company and would catapult the company into the big league."

[topvest] 27/2/2013 21:00

Yes, good results and happy to hold this. They should take their time on acquisitions and ensure that they don't overpay. Patience needed, but I expect a close deal in the next few months.

[dasv] 27/2/2013 17:33

yeah - it has been possible to buy on dips - I had to pay full price today.

[jaws6] 27/2/2013 12:27

dasv
I hold this ,will add more if drop back on bad day

[cestnous] 27/2/2013 12:20

I.C.today
Clinigen makes solid start
TIP UPDATE
Clinigen Group PLC (CLIN)
SPECULATIVE
HIGH RISK
Our previous tip
WE SAIDBuy
WHEN17 January 2013
PRICE220p
TIP PERFORMANCE TO DATE+1%
Half-year results from clinical services group Clinigen (CLIN) revealed significant organic sales growth - which helped drive a 54 per cent rise in underlying profit to £9.7m. Sustaining that heady pace of growth this year could prove challenging, but Clinigen has nonetheless demonstrated that it can grow sales even before adding more products to its existing portfolio.
The greatest organic growth was generated from studies for the biological-based medicines that biotech companies produce. Clinigen CTS, a clinical trials services business, sources comparator medicines for trials and a high number of large anti-viral trials in the half helped to double that division's revenue to £45.1m. However, larger global trials don't generate the sector's best profits, which explains why the segment's profit margin fell from 17 per cent to 13 per cent. Moreover, management doesn't expect the same level of activity in the second half. Meanwhile, the company's products arm, Clinigen SP, supplies the HIV-drug Foscavir and product sales here increased 22 per cent - due to a marketing licence granted in the US. Management reckons that growth rates for Foscavir will settle down, but there's no clear view on when.
Broker Numis Securities expects full-year pre-tax profit of £17.2m, giving EPS of 15.4p (from £15.8m and 14.5p in 2012).
CLINIGEN (CLIN)
ORD PRICE: 223p MARKET VALUE: £184m
TOUCH: 220-225p 12-MONTH HIGH: 230p LOW: 164p
DIVIDEND YIELD: 0.3% PE RATIO: 20
NET ASSET VALUE: 52p* NET CASH: £22.3m
Half-year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p)
2011 32.8 4.03 5.5 nil
2012 61.0 3.66 3.5 0.6
% change +86 -9 -36 -
Ex-div: 6 Mar
Payment: 28 Mar
*Includes intangible assets of £14.7m, or 18p a share
SHARE TIP UPDATE:
A forward PE of 14 isn't that cheap for a healthcare-related play. But Clinigen is searching for a successful product to add to Foscavir and there's impressive organic sales growth in the core business - that more than justifies the rating and we reiterate our buy tip (220p, 17 January 2012). Buy.

[sumitos] 27/2/2013 12:03

It's nice to see a new all time high today. Hope the share price builds from here.

[sumitos] 27/2/2013 12:02

Although we might like to have had a further drug acquisition by now the company are at least focused on delivering this outcome in the second half."Acquisition targets(Clinigen) share price continues to progress well a number of the product acquisition and in-licensing opportunities discussed in the admission document. This is a priority the second half of the financial year. In addition a number of new opportunities have also presented themselves, which the Group is pursuing. Clinigen has also "walked away" from opportunities, where the price expectation went beyond value assessment."

[kambrook] 27/2/2013 09:26

$CLIN.L Clinigen shares up 14p (7%) to 228p on impressive results. Shares have done v well since Sept (2012) IPO at 164p (thru' Numis)

[kambrook] 27/2/2013 09:14

"The second half of the financial year has started well and we remain confident that the underlying performance of the business will enable us to meet our full year expectations."

All looking positive. Strong growth to date and more of the same ahead with a potential boost from any earnings-enhancing acquisitions.

[cestnous] 27/2/2013 09:03

I agree with GHF here; I had expected another purchace here by now. Let's hope that it won't be long in coming, though the divi comments may indicate that this is on the way. Otherwise, excellent results,

[kambrook] 27/2/2013 08:43

"Excitement comes from buying another owned drug to sit alongside Foscavir. It has submitted five orders and with monumental cashflows could buy one perhaps two this year. Buying the right one could have the same implications as a big strike for a small oil company."

So said Small Co. Sharewatch in January when it chose CLIN as one of its top tips for 2013.

Good results today. Plenty of upside potential.

[cfro] 27/2/2013 08:31

Bought a v small amount this morning too. Not cheap by any means but upside potential looks massive. For me, this is more of a punt than anything else.

[rivaldo] 27/2/2013 08:25

I may well have bought in after these results, but for this paragraph:

"Sales in CTS can be lumpy. In H1 there have been particularly strong sales for a number of anti-viral comparator studies amounting to £24.0m, 52% (c.£8m) higher than the equivalent sales in the full year 2011/12. These studies have been largely supplied now and this activity is unlikely to continue at this level into H2"

Which indicates that H2 could be somewhat weak given CLIN's reliance on one or two products.

Will stay on the sidelines for now, which is probably the wrong decision, but still.....good luck all.

[dasv] 27/2/2013 08:18

Bought back in too on these results.

[glasshalfull] 27/2/2013 08:18

sumitos - To be honest, I fully expected an acquisition before now. When SCSW brought these to my intention (Oct/Nov time) it indicated that an acquisition was imminent & they were close to completing up to 5 deals.

Clearly price has been too high & CLIN have walked away.

Irrespective it looks like they are developing nicely & indicate that they should meet market expectations which per Numis forecasts note sales of £97.1m, pretax profit of £17.1m and eps of 14.5p.

So they aren't cheap but look on track to be an excellent GARP share of the future.

ic2 - Nice to see you giving these a look. I've only a few and delighted to tuck them away.

Regards,
GHF

[interceptor2] 27/2/2013 08:13

Brought in today on the back of very good results.

Only had a little chance to research these before the market opened, due to excitement elsewhere. So will research further now.

Pleased to see GHF here already, so I must be on the right track.

ic2...

[sumitos] 27/2/2013 08:08

GHF - I think the other important point is:o On track to add further products to portfolioThis could really ignite the shares if they are able to have the same success as with their current drug. I also liked the maiden dividend. It might be small but shows intent and they do generate a lot of cash so this should help broaden the appeal of the share.